Skip to main content
Clinical Trials/NCT06887920
NCT06887920Active, not recruitingNot Applicable

MultifocAL COntact Lenses for Myopia and Their Effect on Axial Length Elongation in Children

Pauline Kang1 site in 1 country72 target enrollmentStarted: February 11, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
72
Locations
1
Primary Endpoint
Axial length progression

Study Overview

Brief Summary

This study will compare the effects on myopia progression over the course of one year for eyes wearing MiSight 1 Day contact lenses compared to ACUVUE OASYS for PRESBYOPIA contact lenses.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
6 Years to 12 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Aged 6-12 years (inclusive)
  • •Is willing to wear soft contact lenses daily
  • •Spherical equivalent myopic refractive error between -0.50 to -5.00 D in each eye and astigmatism < 1.00 D
  • •Best corrected logMAR visual acuity of 0.1 or better in both eyes
  • •Good ocular and general health
  • •No previous use of myopia control interventions for more than 1 month or within the last 30 days
  • •Competent enough in English to be able to fully understand the participant information and consent form

Exclusion Criteria

  • •Strabismus at distance or near, amblyopia or significant anisometropia (>1D)
  • •Systemic or ocular conditions that may affect contact lens use (e.g., allergy) or that may affect refractive development (e.g., ptosis)
  • •Previous history of ocular surgery, trauma, or chronic ocular disease
  • •Contraindications to contact lens use
  • •Ocular or systemic medication use which may interfere or interact with contact lens wear or ocular development
  • •Plans to migrate or move during the study
  • •Child, parents or guardians not willing to comply with treatment and/or follow-up schedule

Arms & Interventions

Acuvue Oasys for Presbyopia in the RIGHT eye

Other

Acuvue Oasys for Presbyopia in the RIGHT eye and MiSight 1-Day contact lens in the LEFT eye RIGHT eye has intervention, LEFT eye has active comparator

Intervention: Acuvue Oasys for Presbyopia (Device)

MiSight 1-Day in the RIGHT eye

Other

MiSight 1-Day contact lens in the RIGHT eye and Acuvue Oasys for Presbyopia in the LEFT eye RIGHT eye has active comparator, LEFT eye has intervention

Intervention: MiSight 1 Day (Device)

Outcomes

Primary Outcomes

Axial length progression

Time Frame: 1 month, 6 months and 12-months post intervention commencement. Initial protocol also included 3-month time point, but the 3-month visit was updated to a telehealth consultation due to COVID-19 restrictions. Updated after 9 participants.

Change in Axial Length between two eyes measured by laser interferometry (IOL Master)

Cycloplegic autorefraction

Time Frame: 1 month, 6 months and 12-months post intervention commencement. Initial protocol also included 3-month time point, but the 3-month visit was updated to a telehealth consultation due to COVID-19 restrictions. Updated after 9 participants.

Change in Autorefraction between two eyes as measured by autorefractor

Secondary Outcomes

  • Subjective refraction(1 month, 6 months and 12-months post intervention commencement. Initial protocol also included 3-month time point, but the 3-month visit was updated to a telehealth consultation due to COVID-19 restrictions. Updated after 9 participants.)
  • Estimates of outdoor time and near work(1-month, 6-month and 12-month study visits. Also 3-month and 9-month telehealth visits. 3-month visit was changed to telehealth and 9-month visit added after already enrolling 9 participants.)
  • Quality of Life (PREP2)(Baseline, 6-month and 12-month study visits. Added after already enrolling 9 participants.)
  • Quality of Life (PedEyeQ)(Baseline, 6-month and 12-month study visits. Added after already enrolling 9 participants.)
  • Treatment adherence (Questions)(1-month, 6-month and 12-month study visits. Added to initial protocol prior to enrolment commencement.)
  • Treatment adherence (Text-message surveys)(Study month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. 1-month, 6-month and 12-month study visits. Added to initial protocol prior to enrolment commencement.)

Investigators

Sponsor
Pauline Kang
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Pauline Kang

Associate Professor

The University of New South Wales

Study Sites (1)

Loading locations...

Similar Trials